Conquering the Silent Invader: A Spotlight on Colorectal Cancer

In the vast symphony of life, our bodies play a harmonious role, working tirelessly to keep us in perfect rhythm. Yet, amidst this beautiful symphony, a stealthy intruder often lurks in silence, evading our senses until it's too late. Colorectal cancer, the enigmatic foe, affects millions worldwide, and yet its presence often goes unnoticed until it reaches an advanced stage.

Welcome to our journey of unmasking this elusive adversary, as we shed light on the shadows cast by colorectal cancer. Join us as we explore the intricate complexities of this disease, learn about the warning signs it hides, and delve into the remarkable strides of science and compassion in the battle against it.

In this blog, we invite you to embark on a quest for knowledge, empowerment, and hope, as we arm ourselves with the understanding and awareness needed to stand resilient against colorectal cancer's silent advance. Let's shatter the silence and confront this adversary together, weaving our own tapestry of strength, courage, and determination. The time to unmask colorectal cancer is now, and our collective voices will echo far and wide, resonating with the message of prevention, early detection, and triumph.

1) What is colorectal cancer ?

Colorectal cancer, scientifically known as colorectal adenocarcinoma, is a malignant neoplasm that arises from the epithelial cells lining the colon and rectum, which collectively form the lower part of the gastrointestinal tract. As one of the most prevalent forms of cancer, it poses a significant health burden worldwide.

The colon, an integral part of the large intestine, is responsible for absorbing water and electrolytes from indigestible food remnants, while the rectum functions as the terminal part of the large intestine, facilitating the storage and elimination of fecal matter. When cancerous growths, known as tumors, develop in these regions, they can disrupt normal physiological functions, leading to various complications.

In the medical community, the term "colorectal cancer" is often used to encompass both colon cancer and rectal cancer. However, these conditions are distinguished based on their anatomical locations and can exhibit subtle differences in clinical presentations and treatment approaches.

Colorectal cancer typically evolves through a multistep process, known as the adenoma-carcinoma sequence. It begins with the formation of benign polyps, also called adenomas, on the inner lining of the colon or rectum. These polyps are considered precursors to cancer and can gradually progress into malignant tumors if left untreated.

 

2) Causes of Colorectal Cancer

Colorectal cancer, like many other cancers, is a complex disease influenced by a combination of genetic, environmental, and lifestyle factors. While the exact cause of colorectal cancer is not always clear, several risk factors have been identified that can increase the likelihood of developing the disease. Here are some of the key causes and risk factors associated with colorectal cancer:

a) Age: Colorectal cancer risk increases with age. The majority of cases are diagnosed in individuals over the age of 50, with the highest incidence in those over 65.

b) Family History and Genetics: A family history of colorectal cancer or certain genetic syndromes, such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC), also known as Lynch syndrome, can significantly increase the risk of developing colorectal cancer.

c) Personal History of Colorectal Polyps or Cancer: Individuals who have had a history of colorectal polyps or previous colorectal cancer are at higher risk of developing new or recurrent tumors.

d) Inflammatory Bowel Diseases (IBD): Chronic inflammatory conditions of the colon, such as ulcerative colitis and Crohn's disease, can increase the risk of colorectal cancer, especially when the disease is active over an extended period.

e) Diet: A diet high in red and processed meats and low in fiber, fruits, and vegetables has been associated with an increased risk of colorectal cancer.

f) Sedentary Lifestyle: Lack of regular physical activity and a sedentary lifestyle may contribute to an elevated risk of colorectal cancer.

i) Obesity: Being overweight or obese has been linked to an increased risk of developing colorectal cancer.

j) Smoking: Smoking tobacco is a risk factor for several types of cancer, including colorectal cancer.

k) Alcohol Consumption: Heavy alcohol consumption has been associated with an increased risk of colorectal cancer.

l) Diabetes: Individuals with diabetes may have a higher risk of developing colorectal cancer.

m) Race and Ethnicity: Colorectal cancer incidence rates vary among different racial and ethnic groups, with higher rates observed in African Americans.

n) Previous Radiation Therapy: Individuals who have received radiation therapy for previous cancers in the abdominal or pelvic area may have an increased risk of developing colorectal cancer.

It is essential to note that while these risk factors may increase the chances of developing colorectal cancer, having one or more risk factors does not guarantee that an individual will develop the disease. On the other hand, some people without any apparent risk factors may still develop colorectal cancer.

 

3) Prevalence of Colorectal cancer

The incidence of colorectal cancer varies from country to country and is influenced by factors such as demographics, lifestyle, and healthcare access. According to global cancer statistics from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), colorectal cancer is one of the most common cancers worldwide.

As of 2020, it was estimated that there were around 1.93 million new cases of colorectal cancer globally, making it the third most diagnosed cancer after breast and lung cancers. The number of cases can change over time due to changes in population demographics, risk factors, and improvements in cancer diagnosis and reporting.

 

4) Stages of Colorectal Cancer

Colorectal cancer is staged based on the extent of the disease, and the stage determines the prognosis and treatment options. The most commonly used staging system for colorectal cancer is the TNM staging system, which takes into account the tumor size and extent of local invasion (T), lymph node involvement (N), and the presence or absence of distant metastasis (M). Here are the stages of colorectal cancer: 

Stage 0 (In Situ):

In stage 0, also known as carcinoma in situ or colorectal carcinoma in situ, cancerous cells are found only in the innermost lining (mucosa) of the colon or rectum and have not invaded deeper layers or spread to nearby lymph nodes or distant sites. This stage is considered non-invasive.

Stage I:

In stage I, the tumor has grown beyond the innermost lining of the colon or rectum into the submucosa (the layer beneath the mucosa) but has not reached the outer wall of the organ or invaded nearby tissues or lymph nodes. At this stage, cancer has not spread to distant parts of the body.

Stage II:

Stage II is divided into two sub-stages: Stage IIA and Stage IIB.

Stage IIA: Cancer has penetrated through the muscle layer of the colon or rectum but has not reached nearby organs or lymph nodes.

Stage IIB: Cancer has grown through the outer wall of the colon or rectum but has not spread to nearby tissues or lymph nodes.

Stage III:

In stage III, cancer has spread to nearby lymph nodes but has not yet reached distant organs. This stage is further divided into three sub-stages:

Stage IIIA: Cancer has spread to nearby lymph nodes, but the affected lymph nodes are still in the same regional area as the primary tumor.

Stage IIIB: Cancer has grown into or through the outermost layers of the colon or rectum and has spread to nearby lymph nodes.

Stage IIIC: Cancer has spread to nearby lymph nodes in the area of the primary tumor and may involve larger blood vessels or other nearby structures.

Stage IV:

In stage IV, cancer has spread to distant organs or tissues, such as the liver, lungs, peritoneum, or other distant sites. This stage is also known as metastatic colorectal cancer.

Recurrent Colorectal Cancer:

Recurrent colorectal cancer refers to cancer that has returned or spread to other parts of the body after previous treatment.

 

5) Signs and symptoms of Colorectal cancer

Colorectal cancer can be asymptomatic in its early stages, which makes regular screenings vital for early detection. However, as the disease progresses, it may cause various signs and symptoms. Some of the common signs and symptoms of colorectal cancer include:

a) Changes in Bowel Habits: Persistent changes in bowel habits, such as diarrhea, constipation, or a change in the consistency of stools, may be a warning sign.

b) Blood in the Stool: This is one of the most concerning symptoms of colorectal cancer. Blood may appear as bright red or dark-colored and may be visible in the stool or when wiping after a bowel movement.

c) Abdominal Discomfort or Pain: Persistent abdominal pain, cramps, or discomfort, especially if it is accompanied by other symptoms, should be evaluated by a healthcare professional. 

d) Unexplained Weight Loss: Unintended weight loss without any obvious cause or changes in diet or exercise can be a sign of various underlying health issues, including colorectal cancer.

e) Fatigue: Feeling tired or fatigued, even with adequate rest, can be associated with colorectal cancer, especially in more advanced stages of the disease.

f) Anemia: Colorectal cancer can lead to chronic bleeding, resulting in iron deficiency anemia. Symptoms of anemia may include weakness, paleness, and shortness of breath.

g) Narrow Stools: Colorectal cancer may cause a change in the shape of stools, leading to narrow or pencil-like stools.

h) Feeling of Incomplete Bowel Movement: Patients may feel like they need to have a bowel movement, but they are unable to completely evacuate their bowels.

 

6) Colorectal Cancer Screening

Colorectal cancer screening is a crucial preventive measure to detect colorectal cancer in its early stages or even before symptoms develop. Early detection through screening can lead to more successful treatment outcomes and significantly reduce the mortality rate associated with colorectal cancer. Several screening methods are available, and the choice of screening test depends on various factors, including age, risk factors, and personal preferences. Here are some common colorectal cancer screening methods:

a) Colonoscopy: Colonoscopy is considered the gold standard for colorectal cancer screening. During this procedure, a flexible, thin tube with a camera on the end (colonoscope) is inserted into the rectum and advanced through the entire colon. The doctor can visualize the lining of the colon and rectum, identify any abnormalities or polyps, and remove them for further examination or biopsy. Colonoscopy is usually recommended every 10 years starting at age 50 for average-risk individuals.

b) Fecal Immunochemical Test (FIT): FIT is a stool-based test that detects hidden blood in the stool, which may be an early sign of colorectal cancer. It is a simple, non-invasive test that can be done at home. If the FIT result is positive, further evaluation with a colonoscopy is typically recommended.

c) Fecal Occult Blood Test (FOBT): FOBT is another stool-based test that checks for hidden blood in the stool. It is similar to FIT but may use a different method of detecting blood. A positive FOBT result also requires follow-up with a colonoscopy.

d) Flexible Sigmoidoscopy: A flexible sigmoidoscopy is similar to a colonoscopy but examines only the lower part of the colon and rectum. It requires less preparation than a colonoscopy but may miss abnormalities in the upper part of the colon. It is typically recommended every five years along with other screening options.

e) Virtual Colonoscopy (CT Colonography): Virtual colonoscopy is a non-invasive imaging test that uses computed tomography (CT) scans to create detailed images of the colon and rectum. While it does not require insertion of a scope, if abnormalities are found, a colonoscopy may still be needed for further evaluation.

f) USPSTF Screening- The United States Preventive Services Task Force (USPSTF) is an independent, volunteer panel of experts in primary care and prevention that provides evidence-based recommendations on various preventive health services. One of the essential areas of focus for the USPSTF is colorectal cancer screening, including colonoscopy. The USPSTF recommends colorectal cancer screening for adults aged 50 to 75 years, as this age group has the highest risk of developing colorectal cancer

The recommended age to start colorectal cancer screening and the frequency of screening can vary based on individual risk factors and family history. It is essential to discuss screening options with a healthcare professional to determine the most appropriate method and schedule for colorectal cancer screening based on individual health status and risk factors.

Remember, early detection is critical, as it can lead to early intervention and significantly improve the chances of successful treatment and recovery from colorectal cancer.

 7) Treatment for Colorectal Cancer

Colorectal cancer treatments vary depending on the stage of the disease, the size and location of the tumor, the overall health of the patient, and other individual factors. The primary treatment options for colorectal cancer include:

a) Surgery: Colorectal surgery is a specialized field of surgery that deals with the diagnosis and treatment of disorders affecting the colon, rectum, and anus. It involves removing the tumor along with nearby lymph nodes. The extent of surgery may vary based on the tumor's size, location, and stage. In some cases, a minimally invasive approach, such as laparoscopic or robotic surgery, may be used to reduce recovery time and complications.

b) Chemotherapy: Chemotherapy uses powerful drugs to kill or inhibit the growth of cancer cells. It is commonly used in cases of advanced or metastatic colorectal cancer, where the cancer has spread to other parts of the body. It may also be used before or after surgery (neoadjuvant or adjuvant chemotherapy) to shrink the tumor or prevent recurrence.

c) Radiation Therapy: Radiation therapy uses high-energy X-rays or other forms of radiation to target and destroy cancer cells. It is often used in combination with surgery or chemotherapy for locally advanced rectal cancer. In some cases, it may be used to relieve symptoms and improve quality of life for patients with advanced cancer.

d) Targeted Therapies: Targeted therapies are drugs that specifically target certain molecules or receptors on cancer cells, blocking their growth signals and helping the body's immune system fight the cancer. Drugs like bevacizumab and cetuximab are examples of targeted therapies used in colorectal cancer treatment.

e) Immunotherapy: Immunotherapy harnesses the body's immune system to identify and attack cancer cells. It has shown promising results in certain cases of advanced colorectal cancer, particularly for patients with specific genetic mutations, such as microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) tumors.

f) Ablation and Embolization: These are local treatments used for liver metastases from colorectal cancer. Ablation involves using heat or cold to destroy cancerous liver tumors, while embolization blocks the blood supply to the tumor to shrink or control its growth.

g) Palliative Care: Palliative care focuses on managing symptoms and improving the quality of life for patients with advanced or incurable colorectal cancer. It includes pain management, nutritional support, and emotional and psychological care. The choice of treatment or combination of treatments depends on individual factors, including the stage of cancer, the overall health of the patient, and their preferences. Treatment plans are often developed collaboratively by a multidisciplinary team of oncologists, surgeons, radiologists, and other healthcare professionals. It is essential for patients to have open discussions with their healthcare team to understand the benefits and potential side effects of each treatment option and make informed decisions about their care.

 h) Regorafenib for Colorectal Cancer: Regorafenib is an oral targeted therapy medication used in the treatment of advanced colorectal cancer that has progressed despite previous treatments. It belongs to a class of drugs known as multi-kinase inhibitors, which work by blocking certain enzymes and proteins that promote the growth and spread of cancer cells. Regorafenib is approved for use in patients with metastatic colorectal cancer (mCRC) who have previously received other standard treatments, such as chemotherapy, and have shown disease progression. It is usually prescribed when other treatment options have been exhausted. The drug's mechanism of action involves inhibiting several protein kinases, including those involved in angiogenesis (blood vessel formation) and tumor cell proliferation. By blocking these crucial pathways, regorafenib helps to slow down cancer growth and reduces the blood supply to the tumor, thereby limiting its ability to spread. Studies have demonstrated that regorafenib can extend the overall survival and progression-free survival in patients with mCRC who have failed other therapies. It has shown particular effectiveness in patients with certain genetic mutations, such as KRAS and BRAF mutations. Regorafenib is usually taken as a pill once a day in a specific dosage prescribed by the oncologist. As with any medication, regorafenib may cause side effects, and their severity may vary from person to person. Common side effects may include fatigue, hand-foot skin reaction, diarrhea, loss of appetite, weight loss, and high blood pressure. Patients are closely monitored during treatment, and healthcare providers may adjust the dosage or offer supportive medications to manage side effects effectively.

8) Colorectal Cancer Alliance

The Colorectal Cancer Alliance is a nonprofit organization dedicated to supporting and advocating for individuals affected by colorectal cancer. The organization's mission is to empower patients, raise awareness, and fund research to end colorectal cancer in all its forms.

Key Objectives and Activities of the Colorectal Cancer Alliance:

a) Patient Support: The alliance provides resources and support for colorectal cancer patients, survivors, and their caregivers. They offer educational materials, online forums, and helplines to address the physical, emotional, and financial challenges faced by those impacted by the disease.

b) Advocacy: The Colorectal Cancer Alliance advocates for policies and legislation at the local, state, and federal levels to improve colorectal cancer prevention, screening, and treatment. They work to increase funding for research and to promote policies that enhance access to quality care for patients.

c) Awareness and Education: The organization conducts public awareness campaigns to promote early detection and prevention of colorectal cancer. They strive to educate the public about the importance of regular screenings, healthy lifestyle choices, and recognizing the signs and symptoms of the disease.

d) Research Funding: The alliance raises funds to support innovative research aimed at advancing the understanding of colorectal cancer, improving treatment options, and ultimately finding a cure for the disease.

e) Events and Community Engagement: The Colorectal Cancer Alliance organizes various events, such as walks, runs, and fundraisers, to engage the community, raise awareness, and provide opportunities for individuals to show support for those affected by colorectal cancer.

f) Young-Onset Colorectal Cancer Initiative: The alliance has a specific focus on addressing the rising incidence of colorectal cancer in young adults and supports research and advocacy efforts related to young-onset colorectal cancer.

The Colorectal Cancer Alliance collaborates with healthcare providers, researchers, policymakers, and other organizations to make a collective impact in the fight against colorectal cancer. By providing a platform for education, support, and advocacy, the organization aims to reduce the burden of colorectal cancer on individuals and families and ultimately achieve a future free from this disease.

 9) Colorectal Cancer Survival Rate

The survival rate for colorectal cancer varies widely depending on several factors, including the stage at which the cancer is diagnosed, the age and overall health of the patient, and the type of treatment received. Survival rates are usually expressed as the percentage of patients who are alive at a certain point after their diagnosis.

According to the American Cancer Society's most recent data (as of 2021), the 5-year relative survival rate for colorectal cancer is as follows:

a) Localized (confined to the colon or rectum): About 90%

b) Regional (spread to nearby lymph nodes): About 71%

c) Distant (metastasized to other distant organs): About 14%

d) All stages combined: About 65%

It's essential to understand that these survival rates are statistical averages and do not predict the individual outcome for any specific patient. Many factors can influence a person's prognosis, and survival rates can change over time with advances in screening, early detection, and treatment options.

Early detection through regular screening is critical for improving the chances of successful treatment and higher survival rates. Additionally, ongoing research and advancements in medical treatments, including targeted therapies and immunotherapies, have improved outcomes for many patients with colorectal cancer.

If you or someone you know is concerned about colorectal cancer or has received a diagnosis, it's essential to work closely with healthcare professionals to understand the specific situation and develop a personalized treatment plan. Early intervention and appropriate medical care can positively impact the prognosis for individuals diagnosed with colorectal cancer.

 10) Colorectal Cancer Awareness Month

Colorectal Cancer Awareness Month is observed in March each year to raise public awareness about colorectal cancer, its risk factors, prevention, early detection, and treatment options. The awareness month aims to educate the public about the importance of regular screenings, recognizing the signs and symptoms of the disease, and promoting healthy lifestyle choices to reduce the risk of colorectal cancer.

During Colorectal Cancer Awareness Month, various organizations, healthcare providers, patient advocacy groups, and individuals come together to spread information through public events, social media campaigns, educational programs, and community outreach initiatives. The goal is to empower people with knowledge and encourage them to take proactive steps to protect their health and well-being.

Activities during Colorectal Cancer Awareness Month include:

a) Educational Campaigns: Public service announcements, online information resources, and educational materials are disseminated to raise awareness about colorectal cancer and its risk factors.

b) Screening Programs: Healthcare organizations often promote colorectal cancer screening programs and offer reduced or free screening tests to eligible individuals.

c) Fundraising Events: Various fundraising events, such as walks, runs, and charity galas, are organized to support research, patient support services, and awareness campaigns.

d) Social Media Campaigns: Social media platforms are used to share facts, personal stories, and educational content about colorectal cancer throughout the month.

e) Public Talks and Webinars: Expert speakers and healthcare professionals may hold public talks and webinars to address common questions and concerns about colorectal cancer.

f) Survivor Stories: The experiences of colorectal cancer survivors are often shared to inspire hope and emphasize the importance of early detection and treatment.

Colorectal Cancer Awareness Month provides an opportunity for individuals and communities to come together to combat colorectal cancer and support those affected by the disease. By raising awareness and promoting early detection and prevention, we can work towards reducing the impact of colorectal cancer on individuals and families and improving overall health outcomes.

As we draw the curtains on our journey through the realms of colorectal cancer, we find ourselves armed with knowledge, empowered by awareness, and driven by hope. Together, we have shed light on the silent invader, unmasking the enigmatic foe that once lurked in the shadows. We have delved into the intricate complexities of this disease, understanding its risk factors, early signs, and the significance of regular screenings.

In our quest to conquer colorectal cancer, we have witnessed the indomitable spirit of individuals and communities rising to the challenge. From patients bravely fighting the battle to caregivers offering unwavering support, our collective resilience knows no bounds. Advocacy efforts have surged, policymakers have been compelled to act, and research has surged forward in pursuit of breakthroughs that will transform lives.

Through the power of prevention, we have shattered the barriers that once stood in the way of early detection. By uniting our voices, we have turned awareness into action, empowering individuals to take charge of their health and wellbeing. Together, we have forged a formidable alliance against this common adversary.

Yet, as we stand on the precipice of victory, our quest is far from over. The battle against colorectal cancer continues, and we must remain vigilant in our efforts. We shall press on, driven by the unwavering belief that each step we take brings us closer to a future free from this formidable foe.

So, as we bid farewell to this chapter, let us carry forth the torch of knowledge, ignite the flame of awareness, and spread the message far and wide. For in the pursuit of conquering the silent invader, we find strength in unity, power in advocacy, and hope in every beating heart that refuses to surrender.

May our journey inspire change, kindle compassion, and usher in an era where colorectal cancer is but a memory, no longer lurking in the shadows but vanquished by the brilliance of human determination.

Let us continue this fight, hand in hand, with unwavering resolve. Together, we shall forge a future where the spotlight on colorectal cancer shines ever brighter, illuminating the path to a world where the silent invader is no more.

Thank you for joining us on this incredible odyssey. Together, we are the agents of change, the champions of hope, and the architects of a future without colorectal cancer. Until then, let us march onward, fueled by the passion to conquer, the courage to endure, and the belief that we are bound for victory.

References

All the Images are taken from Freepik.com

Center, M. M., Jemal, A., Smith, R. A., & Ward, E. (2009). Worldwide variations in colorectal cancer. CA: a cancer journal for clinicians, 59(6), 366-378.

Iacopetta, B. (2002). Are there two sides to colorectal cancer?. International journal of cancer, 101(5), 403-408.

Stintzing, S. (2014). Management of colorectal cancer. F1000prime reports, 6.

Mármol, I., Sánchez-de-Diego, C., Pradilla Dieste, A., Cerrada, E., & Rodriguez Yoldi, M. J. (2017). Colorectal carcinoma: a general overview and future perspectives in colorectal cancer. International journal of molecular sciences, 18(1), 197.

Eddy, D. M. (1990). Screening for colorectal cancer. Annals of Internal Medicine, 113(5), 373-384.

Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular basis of colorectal cancer. New England journal of medicine, 361(25), 2449-2460.

Haraldsdottir, S., Einarsdottir, H. M., Smaradottir, A., Gunnlaugsson, A., & Halfdanarson, T. R. (2014). Colorectal cancer-review. Laeknabladid, 100(2), 75-82.

Marley, A. R., & Nan, H. (2016). Epidemiology of colorectal cancer. International journal of molecular epidemiology and genetics, 7(3), 10

Granados-Romero, J. J., Valderrama-Treviño, A. I., Contreras-Flores, E. H., Barrera-Mera, B., Herrera Enríquez, M., Uriarte-Ruíz, K., ... & Arauz-Peña, G. (2017). Colorectal cancer: a review. Int J Res Med Sci, 5(11), 4667.

Meyerhardt, J. A., & Mayer, R. J. (2005). Systemic therapy for colorectal cancer. New England journal of medicine, 352(5), 476-487.

Saif, M. W., & Chu, E. (2010). Biology of colorectal cancer. The Cancer Journal, 16(3), 196-201.